- Home
- OTLK vs DTIL Comparison
OTLK vs DTIL Comparison
Compare OTLK & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- DTIL
- Stock Information
- Founded
- OTLK 2010
- DTIL 2006
- Country
- OTLK United States
- DTIL United States
- Employees
- OTLK N/A
- DTIL N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- DTIL Health Care
- Exchange
- OTLK Nasdaq
- DTIL Nasdaq
- Market Cap
- OTLK 48.3M
- DTIL 51.6M
- IPO Year
- OTLK 2016
- DTIL 2019
- Fundamental
- Price
- OTLK $2.25
- DTIL $4.61
- Analyst Decision
- OTLK Strong Buy
- DTIL Strong Buy
- Analyst Count
- OTLK 5
- DTIL 2
- Target Price
- OTLK $9.60
- DTIL $47.00
- AVG Volume (30 Days)
- OTLK 987.3K
- DTIL 591.4K
- Earning Date
- OTLK 08-13-2025
- DTIL 07-31-2025
- Dividend Yield
- OTLK N/A
- DTIL N/A
- EPS Growth
- OTLK N/A
- DTIL N/A
- EPS
- OTLK 0.83
- DTIL N/A
- Revenue
- OTLK N/A
- DTIL $51,141,000.00
- Revenue This Year
- OTLK N/A
- DTIL N/A
- Revenue Next Year
- OTLK $419.06
- DTIL $53.21
- P/E Ratio
- OTLK $2.62
- DTIL N/A
- Revenue Growth
- OTLK N/A
- DTIL N/A
- 52 Week Low
- OTLK $0.87
- DTIL $3.61
- 52 Week High
- OTLK $9.10
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- OTLK 67.03
- DTIL 47.61
- Support Level
- OTLK $2.16
- DTIL $4.27
- Resistance Level
- OTLK $2.45
- DTIL $4.87
- Average True Range (ATR)
- OTLK 0.16
- DTIL 0.25
- MACD
- OTLK 0.05
- DTIL 0.03
- Stochastic Oscillator
- OTLK 81.01
- DTIL 54.43
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.